Concert Pharmaceuticals gains post-IPO

In yet another biotech offering, Concert Pharmaceuticals (CNCE) is at $15.75 in opening trades after pricing its IPO at the top end of the expected $12-$14 range. The IPO size was also bumped to 6M from 5M shares.

In a similar business but further along in clinical trials is Auspex Pharmaceuticals (ASPX +5.7%), which priced its IPO (also after boosting the size) at $12 a week ago and has about doubled since.

More here

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs